Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
about
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsImatinib in chronic myeloid leukemia: an overviewResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDiscovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorKnockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C ReleaseNovel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia CellsA Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor ResistancePYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells.The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyComparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growthA non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprogramingExploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.Genome Fusion Detection: a novel method to detect fusion genes from SNP-array data.Targeted inhibition of kinases in cancer therapyAntileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinibIs there a cloud in the silver lining for imatinib?Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitorsOutcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureAcquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.
P2860
Q24647928-EBA8C594-4694-49BF-B509-FCD27ADCC88FQ26849792-28384287-4877-4D1A-9765-9F266FC34C6DQ26865086-16D7E32A-2C1A-427B-823E-951DB94931FEQ27028181-70CF169B-F9F6-4FA2-A148-EA07F0ED99E4Q27660281-367BD528-B8C3-4C7E-8E99-47D332C96BD0Q28482297-5E03FAA1-9E46-4FCA-9C48-0EB17A4F6B90Q28550350-C7EC7A88-B940-485C-BB86-7597F6645DC6Q28550487-BC24CDD3-453D-4C77-8F7A-9FE346497F87Q28553892-8DED1D0F-97E5-42EC-869D-CC94DD521535Q30837349-FE791747-A9E0-471E-BE5A-76759A026A01Q33418324-7D9AA7DE-751C-47DA-91FA-53E52607873CQ33476874-FBD78D71-15FA-4400-A224-86189FDD3671Q33566582-D594AA03-3743-4690-930B-4E92EBA6CB37Q33588245-DE869924-5502-4D7B-A319-CE9A9F9C53D2Q33767209-8FA4E801-9BE0-4F41-82C8-53F6679BA289Q33828334-08ED7EFE-4537-452A-8089-CF4E83233CFBQ33836021-D76065B2-A849-4F65-96A9-91F6D7A89815Q33844109-BD10058A-E938-4CB2-A8D9-FF9DF1911DE0Q33847866-5D70678C-B28A-4CCB-8D34-525923431332Q33869316-C69F1446-E1F0-4458-B78B-022E3CFCA00DQ33971155-FC2B414C-4074-47E3-8386-69407F0756ACQ34063991-555AE632-DF26-45DF-9DE6-9BBE7ACC52F1Q34183433-AED94B32-2C96-4534-BB35-437E9741E7F5Q34277769-3E668839-3479-424D-8677-C6EB5844187DQ34348134-0788E83C-6A0A-4DF0-85FB-1BE926A48C6BQ34411016-ECEB696C-03CD-4995-A456-CBEE7059BF85Q34557870-AB01C62E-1EE4-42EA-B718-1A1E4E7C9422Q34683348-60C3FE66-E99B-4F1F-80D5-E667912C18A5Q34972671-B07C908E-C3CE-4F1D-813E-5FE6A6809151Q35026699-46CCB41D-6C5D-438B-A633-DC8AB9AB3B52Q35037415-9E2F3F61-60D6-4A53-AA0A-82378779F712Q35040972-5F0429F8-15A1-41F7-88AA-732C4487291EQ35097392-2B10976B-7563-4DD6-914F-B8FD6D6CC34AQ35141800-D47764C9-637C-46B2-A50C-4BB332459E90Q35171271-36459D0C-CD45-473E-867B-8C958B06FD08Q35459748-24068167-395D-4620-9536-CFCD04520AF7Q35596200-8283955E-8FAD-475F-ABF1-7D6998621264Q35612803-0EEB91F0-DCBA-4369-AC05-AC8368EF3DB4Q35642790-397EC431-E3B8-4B1C-84AC-2EC8A7E848C6Q35677075-280DD69B-3209-4FC5-96DD-3E68A4363751
P2860
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Selection and characterization ...... erse mechanisms of resistance.
@en
type
label
Selection and characterization ...... erse mechanisms of resistance.
@en
prefLabel
Selection and characterization ...... erse mechanisms of resistance.
@en
P2093
P4510
P1433
P1476
Selection and characterization ...... verse mechanisms of resistance
@en
P2093
Deininger MW
Goldman JM
Reiffers J
Schultheis B
P304
P407
P577
2000-08-01T00:00:00Z